Brand Name(s): Skelaxin
CAS nº: 1665-48-1
(me tax’ a lone)
About Metaxalone
This reference site is dedicated exclusively to metaxalone.
It provides you with the most extensive product information and up-to-date resources regarding this medication, including related news articles, medical studies, an image library and all the necessary information on dosage and side effects.
Whether you are an average consumer or a pharma industry professional, you can now find out everything you need to know about metaxalone, as well as take part in our open discussion forum by sharing your own knowledge and experiences with people who are using this medication.
This unique site will also provide you with inside industry news on which companies or organizations are playing an important part in its research, development, production and promotion. It is your one-stop site for a total metaxalone experience!
Why is this medication prescribed?
Metaxalone relaxes muscles and is used for short-term, painful muscular conditions in which muscles are in spasm.
It is used in addition with physical therapy and stretching of muscles. It works by blocking nerve impulses (or pain sensations) that are sent to your brain.
Metaxalone is marketed by King Pharmaceuticals under the brand name Skelaxin®. It is still under patent therefore it is still not available in a generic form.
Latest News
King Pharmaceuticals Reports FDA Approval of New Skelaxin(R) Label
King Pharmaceuticals (NYSE: KG) reported today that the U.S. Food and Drug Administration ("FDA")...
[more]Eon labs says generic muscle drug to be delayed
Eon Labs Inc. said its generic version of the Elan Corporation's Skelaxin muscle relaxant would be...
[more]King Pharmaceuticals Reports First-Quarter 2006 Financial Results
King Pharmaceuticals, Inc. KG announced today that total revenues increased 31% to $484 million...
[more]Elan raises €55m in new sell-off
Irish pharmaceutical group Elan has raised around $70 million (€55m) from four new deals, including...
[more]King Pharmaceuticals posted a monthly rise of 31%, sparked by favorable second-quarter results
The generic-drug maker posted earnings of 44 cents per share, exceeding the Street estimate by 24...
[more]